Novartis psoriasis drug maintains efficacy after 4 years - study

ZURICH, Oct 1 (Reuters) - Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson .